Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Polycystic Ovarian Syndrome Therapeutics Report 2016 - Pipeline Review of 7 Companies & 9 Drug Profiles - Research and Markets

Research and Markets
Posted on: 30 Sep 16

Research and Markets has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H2 2016" report to their offering.

'Polycystic Ovarian Syndrome - Pipeline Review, H2 2016'; Polycystic Ovarian Syndrome pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities Institutes.

Furthermore, the publisher says; Polycystic Ovarian Syndrome Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.

The report 'Polycystic Ovarian Syndrome - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Polycystic Ovarian Syndrome Overview
  3. Therapeutics Development
  4. Pipeline Products for Polycystic Ovarian Syndrome - Overview
  5. Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis
  6. Polycystic Ovarian Syndrome - Therapeutics under Development by Companies
  7. Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes
  8. Polycystic Ovarian Syndrome Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Polycystic Ovarian Syndrome - Products under Development by Companies
  13. Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes
  14. Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
  • Addex Therapeutics Ltd
  • Crinetics Pharmaceuticals, Inc.
  • EffRx Pharmaceuticals S.A.
  • Euroscreen S.A.
  • Merck KGaA
  • Millendo Therapeutics, Inc.
  • Vicore Pharma AB

For more information about this report visit

View source version on

Business Wire

Last updated on: 30/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.